相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Primary therapy and relative survival in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinaemia: a population-based study in the Netherlands, 1989-2018
Karima Amaador et al.
BRITISH JOURNAL OF HAEMATOLOGY (2022)
Long-term follow-up of ibrutinib monotherapy in treatment-naive patients with Waldenstrom macroglobulinemia
Jorge J. Castillo et al.
LEUKEMIA (2022)
Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenstrom Macroglobulinemia
Steven P. Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Evaluating Patients' Preferences Regarding Treatment Options for Waldenstrom's Macroglobulinemia, a Discrete-Choice-Experiment
Karima Amaador et al.
BLOOD (2021)
Trends in Incidence and Mortality of Waldenstrom Macroglobulinemia: A Population-Based Study
Xuejiao Yin et al.
FRONTIERS IN ONCOLOGY (2020)
How I treat Waldenstrom macroglobulinemia
Meletios A. Dimopoulos et al.
BLOOD (2019)
Waldenstrom's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
E. Kastritis et al.
ANNALS OF ONCOLOGY (2018)
Fifty-Year Incidence of Waldenstrom Macroglobulinemia in Olmsted County, Minnesota, From 1961 Through 2010: A Population-Based Study With Complete Case Capture and Hematopathologic Review
Robert A. Kyle et al.
MAYO CLINIC PROCEEDINGS (2018)
Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstrom's Macroglobulinemia
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Waldenstrom macroglobulinemia treatment algorithm 2018
Morie A. Gertz
BLOOD CANCER JOURNAL (2018)
Treatment recommendations from the Eighth International Workshop on Waldenstrom's Macroglobulinemia
Veronique Leblond et al.
BLOOD (2016)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Response rate to the treatment of Waldenstrom macroglobulinemia: A meta-analysis of the results of clinical trials
A. Santos-Lozano et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Ibrutinib in Previously Treated Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
Mathias J. Rummel et al.
LANCET (2013)
MYD88 L265P Somatic Mutation in Waldenstrom's Macroglobulinemia
Steven P. Treon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Diagnosis and Management of Waldenstrom Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines
Stephen M. Ansell et al.
MAYO CLINIC PROCEEDINGS (2010)
Primary Therapy of Waldenstrom Macroglobulinemia With Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180
Steven P. Treon et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Comparative Outcomes Following CP-R, CVP-R, and CHOP-R in Waldenstrom's Macroglobulinemia
Leukothea Ioakimidis et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide
Meletios Athanasios Dimopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Clinicopathologic features of Waldenstrom's macroglobulinemia and marginal zone lymphoma: Are they distinct or the some entity?
FO Berger et al.
CLINICAL LYMPHOMA (2005)
Initial immunoglobulin M 'Flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia an eastern cooperative oncology group study
IM Ghobrial et al.
CANCER (2004)
Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia:: Consensus panel recommendations from the second international workshop on Waldenstrom's macroglobulinemia
RA Kyle et al.
SEMINARS IN ONCOLOGY (2003)
Treatment of Waldenstrom's macroglobulinemia with rituximab
MA Dimopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
分享论文
